An official website of the United States government
Substances
Topics
- Substance Misuse Prevention
- Tobacco Smoke & Health
- Fetal Alcohol Spectrum Disorders (FASD)
- Alcohol Misuse and Alcohol Use Disorder
- Underage Drinking
- Cannabidiol Research
- Cannabinoid Research
- Cocaine
- Electronic Nicotine Delivery Systems
- Endocannabinoid System Research
- Fentanyl Misuse & Addiction
- Harm Reduction for Substance Misuse
- Methamphetamine
- Opioid Misuse & Addiction
- Opioids
- Prescription Drug Misuse
- Recovery Support Services
- Screening & Brief Intervention for Substance Misuse
- Stimulant Use and Misuse
- Substance Misuse
- Therapeutic Cannabinoid Research
- Tobacco
Clinic-Randomized Trial of Clinical Decision Support for Opioid Use Disorders in Medical Settings (NIH HEAL Initiative)
Funded by the NIH HEAL Initiative®
This project will implement an OUD-Clinical Decision Support system in a large multi-site randomized controlled trial to evaluate its impact on practice process measures and patient outcomes; study facilitators and barriers to implementation and determine the costs of implementation and maintenance.
Rebecca Rossom, M.D., M.S.C.R.
Clinical Research Investigator
HealthPartners Institute for Education & Research
P.O. Box 1524, Mailstop 23301A , Minneapolis, MN, 55440, US
Validation of a Community Pharmacy-based Prescription Drug Monitoring Program Risk Screening Tool (PHARMSCREEN) (NIH HEAL Initiative)
Funded by the NIH HEAL Initiative®
The primary objective of this study is to evaluate the criterion and concurrent validity of the Narcotic Score (NS metric) as a clinical measure of opioid misuse and use disorder and establish risk level thresholds within community pharmacies - an optimal - yet underutilized setting for identification and engagement of patients with opioid risk.
Gerald Cochran, MSW, Ph.D.
Associate Professor
University of Utah Health
383 Colorow Way, Mailbox 16, Salt Lake City, UT, 84108, US
Preventing and Identifying Opioid Use Disorder using the Six Building Blocks (6BBs) for Improving Opioid Prescription Management (NIH HEAL Initiative)
Funded by the NIH HEAL Initiative®
This project seeks to develop and test a “train the trainer” curriculum and training experience that will facilitate the spread and use of the Six Building Blocks (6BBs) by adapting the 6BBs framework and toolkit for health systems and other organizations, training personnel to facilitate its implementation, and monitoring results of this implementation
Laura-Mae Baldwin, MD, MPH
Professor
University of Washington
Institute of Translational Health Sciences
Seattle, WA, 98105-4982, US
Innovatively Increasing PCP Prescribing of Buprenorphine: Measurement Based Care and Integrated Electronic Solution (NIH HEAL Initiative)
Funded by the NIH HEAL Initiative®
Medication Treatment for Opioid-dependent Expecting Mothers (MOMs): A Pragmatic Randomized Trial Comparing Two Buprenorphine Formulations (NIH HEAL Initiative)
Funded by the NIH HEAL Initiative®
Human "Brain Bank" Tissue for Alcohol Research | National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Human "Brain Bank" Tissue for Alcohol Research
To facilitate alcohol-related research, NIAAA is currently supporting the collection of autopsied human brain tissue from individuals with alcohol use disorder and from controls for distribution to qualified alcohol research investigators. Tissue collection and distribution is provided by the Brain Tissue Resource Center (BTRC), University of Sydney, Australia.
Gabriella Miller Kids First Pediatric Research Program
Determining the Optimal Duration of Buprenorphine Treatment to Reduce the Risk of Relapse, Overdose, and Mortality (NIH HEAL Initiative)
Funded by the NIH HEAL Initiative®
Collaborative Care for Polysubstance use in Primary Care Settings (Co-Care) (NIH HEAL Initiative)
Funded by the NIH HEAL Initiative®
A Foundation to Examine Reasons for Discontinuation for Buprenorphine Care in the Veterans Health Administration (NIH HEAL Initiative)
Funded by the NIH HEAL Initiative®
This study will include analyses of VA databases to examine patient and organizational characteristics associated with buprenorphine termination during outpatient treatment for opioid use disorder. These analyses are critical for generating data and forming further hypotheses on how to implement targeted approaches to improve retention in treatment.
Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO
Professor of Medicine and Psychiatry
University of Utah Health